* No published clinical trials exist to confirm the safety or effectiveness of the product
The clinical relevance of these results seems also highlighted by the evidence that for some outcomes the clinical benefit is consistent irrespective of the presence of type 2 diabetes [13], advanced age [13, 30], and the background cardiorenal disease [12, 15, 31]
No downtime is required
Novo Nordisks recent data shows that the company is able to keep up with supply and demand requirements
[3] [4] Clinical trials have demonstrated substantial reductions in hemoglobin A1c (up to 2.5% reduction from baseline) and body weight (up to 20% reduction from baseline) in the SURPASS and SURMOUNT clinical trial programs
In one particular study, 957 participants were involved, all of whom had a BMI of 30 or higher, were over 18 years old, and were non-diabetic